Roquette Acquires Itacel

News
Article

Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.

On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the previously announced acquisition of Itacel. Itacel is an excipient division of Blanver, a Brazilian multinational company specializing in the development, manufacture, and commercialization of raw materials and drugs.

The acquisition is part of a series of investments made by Roquette to position itself globally, according to the company. Financial details of the closing are unpublicized.

Source: Roquette

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content